JP2023521218A5 - - Google Patents
Info
- Publication number
- JP2023521218A5 JP2023521218A5 JP2022562556A JP2022562556A JP2023521218A5 JP 2023521218 A5 JP2023521218 A5 JP 2023521218A5 JP 2022562556 A JP2022562556 A JP 2022562556A JP 2022562556 A JP2022562556 A JP 2022562556A JP 2023521218 A5 JP2023521218 A5 JP 2023521218A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- car
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010301357.9A CN113527507A (zh) | 2020-04-16 | 2020-04-16 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| CN202010301357.9 | 2020-04-16 | ||
| PCT/CN2021/085062 WO2021208750A1 (zh) | 2020-04-16 | 2021-04-01 | 靶向cd22的嵌合抗原受体及其制法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521218A JP2023521218A (ja) | 2023-05-23 |
| JP2023521218A5 true JP2023521218A5 (https=) | 2024-04-11 |
Family
ID=78083511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562556A Pending JP2023521218A (ja) | 2020-04-16 | 2021-04-01 | Ｃｄ２２標的キメラ抗原受容体、その調製方法、及びその適用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230144447A1 (https=) |
| EP (1) | EP4151653A4 (https=) |
| JP (1) | JP2023521218A (https=) |
| KR (1) | KR20220167330A (https=) |
| CN (1) | CN113527507A (https=) |
| AU (1) | AU2021255412A1 (https=) |
| CA (1) | CA3179551A1 (https=) |
| WO (1) | WO2021208750A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116462770B (zh) * | 2023-04-18 | 2024-03-08 | 科弈(浙江)药业科技有限公司 | Cd19的人源化抗体和一种表达双特异性嵌合抗原受体的car-t细胞及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| EP2032606B1 (en) | 2006-05-30 | 2013-11-27 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| US8481683B2 (en) * | 2006-12-01 | 2013-07-09 | Medarex, Inc. | Human antibodies that bind CD22 and uses thereof |
| WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
| MX361533B (es) | 2012-04-26 | 2018-12-07 | Bioatla Llc | Anticuerpos anti-cd22. |
| MX2018004503A (es) * | 2015-10-15 | 2019-04-15 | Us Health | Receptores de antigeno quimerico anti-cd30. |
| CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| BR112019006781A2 (pt) * | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| CN107964549B (zh) * | 2016-10-20 | 2020-12-08 | 上海恒润达生生物科技有限公司 | 靶向cd22的嵌合抗原受体及其用途 |
| AU2018246377B2 (en) * | 2017-03-31 | 2025-01-30 | Cellectis Sa | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
| US10543263B2 (en) * | 2017-10-16 | 2020-01-28 | Lentigen Technology Inc. | Compositions and methods for treating cancer with anti-CD22 immunotherapy |
| WO2019094360A1 (en) * | 2017-11-07 | 2019-05-16 | The Board Of Regents Of The University Of Texas System | Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer |
| CN109836495A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd22的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN116836297A (zh) * | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| CN112312930A (zh) * | 2018-05-02 | 2021-02-02 | 宾夕法尼亚大学董事会 | 磷脂酶a2受体嵌合自身抗体受体t细胞的组合物和方法 |
| CN108715859B (zh) * | 2018-05-31 | 2021-08-03 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向cd22的嵌合抗原受体及其应用 |
| US12036242B2 (en) * | 2018-07-05 | 2024-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T cells that target B-cell antigens |
-
2020
- 2020-04-16 CN CN202010301357.9A patent/CN113527507A/zh active Pending
-
2021
- 2021-04-01 KR KR1020227039524A patent/KR20220167330A/ko active Pending
- 2021-04-01 JP JP2022562556A patent/JP2023521218A/ja active Pending
- 2021-04-01 EP EP21788934.4A patent/EP4151653A4/en active Pending
- 2021-04-01 CA CA3179551A patent/CA3179551A1/en active Pending
- 2021-04-01 AU AU2021255412A patent/AU2021255412A1/en active Pending
- 2021-04-01 US US17/918,414 patent/US20230144447A1/en active Pending
- 2021-04-01 WO PCT/CN2021/085062 patent/WO2021208750A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031784A5 (https=) | ||
| CN109069638B (zh) | 用于癌症治疗的三特异性抑制剂 | |
| JP7428663B2 (ja) | いくつかの多重抗原の標的用の逆ユニバーサルキメラ抗原受容体を発現する免疫細胞ならびにその製造方法ならびに癌、感染症および自己免疫疾患を治療するためのその使用 | |
| CN113227146B (zh) | 密蛋白18.2结合部分和其用途 | |
| ES2565481T3 (es) | Anticuerpo anti-PlGF novedoso | |
| EP3459597A1 (en) | Single domain antibody for ctla4 and derived protein thereof | |
| JP2019530431A5 (https=) | ||
| WO2022057871A1 (zh) | 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| EP2172484A2 (en) | Serum albumin binding proteins | |
| BR112014003769B1 (pt) | Molécula de ligação ao antígeno biespecífica ativadora de célula t, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
| JP2024500839A (ja) | 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用 | |
| IL319311A (en) | Low pH pharmaceutical composition containing T cells involved in antibody constructs | |
| JP2022542559A5 (https=) | ||
| JP2023543493A (ja) | ヒトクローディン１８．２を標的とする抗体及びその使用 | |
| CN119053347A (zh) | 免疫抗原特异性il-18免疫细胞因子及其用途 | |
| EP4154910A1 (en) | Binding protein having h2l2 and hcab structures | |
| CN111655733A (zh) | 共价多特异性抗体 | |
| JP2023524811A5 (https=) | ||
| JP2022512734A (ja) | エキソソーム標的化二重特異性抗体 | |
| JP2024516308A5 (https=) | ||
| WO2024012457A1 (zh) | 三特异性抗体及其用途 | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2023521218A5 (https=) | ||
| WO2023232022A1 (zh) | 靶向pd-l1和vegf的重组融合蛋白及其制备和用途 | |
| JP2023554467A5 (https=) |